Tech Company Financing Transactions
Axon Therapies Funding Round
Axon Therapies, based in New York, secured $32 million in funding from Earlybird Venture Capital, Sante Ventures and CD Capital.
Transaction Overview
Company Name
Announced On
9/26/2025
Transaction Type
Venture Equity
Amount
$32,000,000
Round
Undisclosed
Investors
Earlybird Venture Capital (Lead Investor)
Sante Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate its next phase of clinical development, including two double-blinded randomized feasibility studies in heart failure, a condition that affects millions of people worldwide with limited treatment options.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
345 Park Ave S
New York, NY 10010
USA
New York, NY 10010
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Axon Therapies, a private medtech company, was founded to bring more treatment options to heart failure patients, especially those with preserved ejection fraction. We developed the SAVM procedure, a simple and novel approach to modulating the body's sympathetic nervous system to restore balance in the circulatory system, with the goal of improving functional capacity and quality of life for heart failure patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Zoar Engelman
Browse more venture capital transactions:
Prev: 9/26/2025: BotCity venture capital transaction
Next: 9/26/2025: Valence by Get Pegasus venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs